论文部分内容阅读
替莫瑞林醋酸盐(tesamorelin,商品名为Egrifta)由加拿大Theratechnologies公司研制,2010年11月10日经美国FDA批准在美国由EMD Serono公司独家上市,用于HIV相关性脂肪代谢障碍的治疗,是FDA批准的首个用于治疗脂肪代谢障碍的药物[1]。Egrifta有效成分为替莫
The tesimorelin (brand name Egrifta) was developed by Theratechnologies Inc. of Canada and was exclusively marketed by the EMD Serono Company in the United States on November 10, 2010 for the treatment of HIV-related lipodystrophy , Is the first drug approved by FDA for the treatment of lipodystrophy [1]. The active ingredient of Egrifta is Tim